Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

Authors not listed

Graybug Vision · 2017

Abstract

The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2017). A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration. <em>Graybug Vision</em>. https://clinicaltrials.gov/study/NCT03249740
Vancouver
Anonymous. A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration. Graybug Vision. 2017.
BibTeX
@misc{anon2017APhase, title = {A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration}, author = {Anonymous}, journal = {Graybug Vision}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings